EirGenix Inc. has delivered news regarding the receipt of a marketing endorsement from the European Commission for their trastuzumab biosimilar medication (EG12014).

Vertex Pharmaceuticals has announced that the European Commission has approved an expanded label for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat cystic fibrosis in children aged 2 to 5 with at least one F508del mutation in the CFTR gene.

Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. revealed that the first volunteer has been enlisted for the initial Phase I clinical examination of its innovative antibiotic MRX-5 in Australia.

Origen Chengdu and Vanotech have declared the first patient has received their gene therapy in the Phase 1 trial of VAN-2201 for Wet Macular Degeneration associated with aging.

At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.

HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.

Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.

European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.

ProMIS Neurosciences initiates Phase 1a clinical trial, injecting the first participants with PMN310, a potential Alzheimer’s Disease treatment.

Immix Biopharma confirms IND application for CAR-T NXC-201 has been sanctioned by FDA, allowing treatment dosage for U.S. patients.

The biopharmaceutical company Omnix Medical, known for creating advanced anti-infectives to combat serious infections, has reported today that their upcoming Phase II trial for their innovative anti-infective, OMN6, has received approval from the FDA.

The OCEANIC-AF phase III trial comparing asundexian and apixaban in stroke-risk atrial fibrillation patients will end early. This is based on the Independent Data Monitoring Committee's recommendation, as asundexian showed lower efficacy than the control. Bayer will analyze the data further and share the results later.